ConvaTec Group PLC (LON:CTEC) Receives GBX 319 Average PT from Brokerages

Shares of ConvaTec Group PLC (LON:CTEC) have received an average recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued a report on the stock in the last year is GBX 319.

A number of research firms have issued reports on CTEC. Stifel Nicolaus reissued a “buy” rating and issued a GBX 315 target price on shares of ConvaTec Group in a research report on Wednesday, March 11th. Berenberg Bank upped their price target on ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, Citigroup reiterated an “outperform” rating and set a GBX 315 price target on shares of ConvaTec Group in a research note on Thursday, March 5th.

ConvaTec Group Price Performance

ConvaTec Group stock opened at GBX 236 on Thursday. ConvaTec Group has a 12 month low of GBX 209.40 and a 12 month high of GBX 311.20. The company has a current ratio of 1.53, a quick ratio of 0.96 and a debt-to-equity ratio of 106.19. The business’s 50 day simple moving average is GBX 235.55 and its 200 day simple moving average is GBX 236.71. The company has a market cap of £4.60 billion, a price-to-earnings ratio of 27.44, a PEG ratio of 0.93 and a beta of 0.76.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.